安罗替尼联合三维适形放射治疗对中晚期食管癌患者循环肿瘤细胞、肿瘤标志物及生存率的影响  

Effects of Anlotinib Combined with Three-Dimensional Conformal Radiation Therapy on Circulating Tumor Cells,Tumor Markers and Survival Rate in Patients with Medium-Term and Advanced Esophageal Cancer

作　　者：奚和明 赵雪松 杨振宇 XI He-ming;ZHAO Xue-song;YANG Zhen-yu(Department of Oncology and Radiology,Anyang People's Hospital,Anyang 455000,China)

机构地区：[1]安阳市人民医院肿瘤放射科,安阳455000

出　　处：《中国合理用药探索》2024年第10期59-66,共8页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨安罗替尼联合三维适形放射治疗(3DCRT)对中晚期食管癌患者循环肿瘤细胞(CTCs)、肿瘤标志物及生存率的影响。方法:选取2019年1月~2020年8月期间某院收治的150例中晚期食管癌患者作为研究对象,采用随机数字表法分为对照组和观察组,每组75例。两组患者均给予常规治疗,对照组患者给予3DCRT,观察组患者在对照组治疗基础上加用盐酸安罗替尼胶囊。比较两组患者临床疗效、CTCs、血管生成因子[转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)]、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCCA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、并发症发生情况及生存率。结果:治疗后,观察组患者临床缓解率(65.33%)高于对照组(42.67%,P<0.05);两组患者CTCs均降低,且观察组低于对照组(P<0.05);两组患者血清TGF-β1、VEGF和MMP-9水平均降低,且观察组均低于对照组(P<0.05);两组患者血清CEA、SCCA和CYFRA21-1水平均降低,且观察组均低于对照组(P<0.05)。重复测量方差分析显示,两组患者血清CTCs、TGF-β1、VEGF、MMP-9、CEA、SCCA和CYFRA21-1水平组间效应、时间效应和交互效应比较均具有统计学差异(P<0.05)。治疗期间,两组患者并发症总发生率比较无统计学差异(P>0.05)。观察组患者随访2年和3年的生存率均高于对照组(P<0.05)。结论:安罗替尼联合3DCRT可显著提高中晚期食管癌患者的临床疗效,降低CTCs、肿瘤标志物水平,抑制肿瘤血管新生,提高生存率,且未增加并发症的发生风险。Objective:To investigate the effects of anlotinib combined with three-dimensional conformal radiation therapy(3DCRT)on circulating tumor cells(CTCs),tumor markers and survival rate in patients with medium-term and advanced esophageal cancer.Methods:A total of 150 patients with medium-term and advanced esophageal cancer treated in a certain hospital from January 2019 to August 2020 were selected and divided into the control group and observation group using the random number table method,with 75 patients in each group.Both groups were given conventional treatment,the control group was given 3DCRT,and the observation group was given anlotinib hydrochloride capsules in addition to the treatment given in the control group.The clinical efficacy,CTCs,angiogenic factors[transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9)],tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCCA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],complications and survival rate were compared between the two groups.Results:After treatment,the clinical response rate in the observation group(65.33%)was higher than that in the control group(42.67%,P<0.05).The CTCs was decreased in both groups,and lower in the observation group than that in the control group(P<0.05).The serum levels of TGF-β1,VEGF and MMP-9 were decreased in both groups,and lower in the observation group than those in the control group(P<0.05).The serum levels of CEA,SCCA and CYFRA21-1 were decreased in both groups,and lower in the observation group than those in the control group(P<0.05).The repeated measures ANOVA demonstrated statistically significant differences in between-group effects,time effects and interaction effects for serum CTCs,TGF-β1,VEGF,MMP-9,CEA,SCCA and CYFRA21-1 levels between the two groups(P<0.05).During the treatment period,there was no statistically significant difference in the total incidence of complications between the two groups(P>0.05).The 2-year and 3-year sur

关 键 词：食管癌 安罗替尼 三维适形放射治疗 循环肿瘤细胞 并发症 

分 类 号：R735.1[医药卫生—肿瘤]